Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.67 Consensus Price Target from Brokerages
Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) have been given an average rating of “Buy” by the eight brokerages that are covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month […]
Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) have been given an average rating of “Buy” by the eight brokerages that are covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month […]
